In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, reflects on the gap between sponsor expectations and statistical reality, drawing on lessons from the COVID era to argue for more ...

In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, examines the most common threats to trial data reliability, including opaque methodologies, synthetic controls, and the limits of ...

A new review of multiple studies suggests that regular physical activity can significantly lower anxiety and depressed moods ...

The literature on physician-mediated interventions to reduce costs is scant and provides little guidance on effective strategies. Objectives: Provider organizations are increasingly entering ...

Allogene Therapeutics Inc (ALLO) extends its cash runway into 2028 while focusing on pivotal clinical milestones and innovative treatment strategies.

Objective: To conduct a cost-effectiveness analysis comparing behavioral health integration (BHI) in primary care vs clinical decision support (usual care) for adult pat ...

G&A Expenses -- $13.8 million in the fourth quarter, of which $5.6 million was non-cash stock-based compensation; annual G&A ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

Patients who received narrative-based palliative care also reported better quality of life, improved sleep quality, and greater acceptance of death compared with patients receiving routine care. These ...

Vertical health delivery programmes were highly effective in rapid roll-out of HIV services in high-burden countries in ...

The FDA declined to endorse leucovorin as a treatment for autism, but approved the drug to treat cerebral folate deficiency, ...

Good morning, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix. And we're very pleased to welcome you today to our investor call and webcast to ...